Catherine Conahan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catherine Conahan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Andrea J. Bullock
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
19 shared publications - Benjamin L. Schlechter
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
19 shared publications - Bruno Bockorny
Division of Medical Oncology, Beth Israel Deaconess Medical Center
19 shared publications Christine Lim
19 shared publicationsDipikaa Akshinthala
19 shared publications- Douglas K. Pleskow
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
19 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Purpose:Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug sensitivity and correlation with clinical outcomes.Experimental Design:PDOs were established from a heterogeneous population of patients with PDAC including both basal and classical PDAC subtypes.Results:A method for classifying PDOs as sensitive or resistant to chemotherapy regimens was developed to predict the clinical outcome of patients. Drug sensitivity testing on PDOs correlated with clinical responses to treatment in individual patients.Conclusions:These data support the investigation of PDOs to guide treatment in prospective interventional trials in PDAC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Purpose:Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug sensitivity and correlation with clinical outcomes.Experimental Design:PDOs were established from a heterogeneous population of patients with PDAC including both basal and classical PDAC subtypes.Results:A method for classifying PDOs as sensitive or resistant to chemotherapy regimens was developed to predict the clinical outcome of patients. Drug sensitivity testing on PDOs correlated with clinical responses to treatment in individual patients.Conclusions:These data support the investigation of PDOs to guide treatment in prospective interventional trials in PDAC.